• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

VZVΔG-ZEBOV vaccine may be effective in preventing Ebola virus infection

byJeffrey CohenandPriyanka Vedak
March 5, 2015
in Infectious Disease
Reading Time: 3 mins read
2 Minute Medicine Rewind November 23 – November 30, 2014
Share on FacebookShare on TwitterShare on LinkedIn

1. In this report of a 44-year-old male exposed to Ebola virus through a needle stick in Sierra Leone, vaccination with an experimental vaccine (VZVDG-ZEBOV) was effective in preventing Ebola virus infection.

2. Laboratory analysis indicated an innate and adaptive immune response after administration of the VZVDG-ZEBOV vaccine.

Evidence Rating Level: 3 (Average)   

Study Rundown: A 44-year-old male physician from the United States sustained a needle stick injury through gloves that had been in contact with severely ill Ebola patients in Sierra Leone. He cleaned the area and the patient was prepared for medical evacuation to the US. The patient agreed to receive an experimental Ebola vaccine (VZVDG-ZEBOV), a replicating, attenuated, recombinant vesicular stomatitis virus with a glycoprotein replaced by an Ebola virus glycoprotein. It can be used for vaccination in both preventative and postexposure settings. Prior to this case, the VZVDG-ZEBOV vaccine had been used in only one other human. This case report details the patient’s response to the vaccination and demonstrates the time course to symptomatic and laboratory resolution of the virus. It additionally highlights both the innate and adaptive immune responses activated by the vaccine. At 4 month follow up, the patient continues to be asymptomatic and is doing well.

Strengths of this study include the careful monitoring and recording of the clinical course of the patient and the fact that this is one of the first reports of a human receiving the VZVDG-ZEBOV Ebola vaccine. While the case report reveals promising results regarding the safety and efficacy of the VZVDG-ZEBOV vaccination, larger studies are needed to fully vet its potential.

Click to read the study, published today in JAMA

RELATED REPORTS

WHO says Nigeria has no active Ebola cases after patient is evacuated to Switzerland

The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children

Click to read an accompanying editorial in JAMA

Relevant Reading: Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

In-Depth [case report]: This study documents the experience of a 44-year-old American physician exposed to Ebola virus while working in Sierra Leone who received an experimental vaccine (VZVDG-ZEBOV) to prevent Ebola virus infection. He received the vaccine 43 hours after exposure. Twelve hours after vaccine administration, he developed nausea, myalgias, chills, and malaise. These symptoms resolved by day 7. Over the course of this time, he also had fevers (as high as 39.1 degrees Celsius) and mildly low oxygen saturations (94-96%). He also had leukopenia, thrombocytopenia, lymphopenia, and an elevated D-dimer. PCR studies were consistently negative for Ebola virus infection. Nine days after vaccine administration, he was discharged home to complete a 21-day isolation period. He then returned to work and was doing well four months later. Laboratory analysis throughout his course indicated both innate and adaptive immune responses in response to the VZVDG-ZEBOV vaccine, with a serum IgM against the Ebola virus glycoprotein detected on day 17 and a serum IgG initially detected on day 17 and an increased level detected on day 34. T cell activation was noted on day 2.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ebolavaccine
Previous Post

Hepatitis E vaccine may protect for up to 4.5 years

Next Post

ADHD associated with increased mortality rates

RelatedReports

An artistic representation of the African continent with a depiction of the Ebola virus above it, suggesting an outbreak context.
2MM Trial Briefs

WHO says Nigeria has no active Ebola cases after patient is evacuated to Switzerland

October 28, 2026
Two vaccine vials on a balance scale, with graphic representations of viruses in the background, symbolizing vaccines for infectious diseases.
Emergency

The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children

September 21, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Chronic Disease

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

February 26, 2026
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Chronic Disease

The Scan by 2 Minute Medicine®: Daily caffeine intake linked to lower dementia risk, AAP sues over federal vaccine schedule overhaul, Catherine O’Hara passes away after short illness, and GLP-1 receptor agonists reduce endometrial cancer risk

February 11, 2026
Next Post
Pre-operative transcranial magnetic stimulation useful for language mapping

ADHD associated with increased mortality rates

Post-mastectomy breast reconstruction may improve survival outcomes

Classics Series, Landmark Trials in Medicine

Head cooling improves outcomes in neonatal encephalopathy [Classics Series]

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.